By DANTELA LACQUES / Staff reporterWASHINGTON (Reuters) – The U.S. Food and Drug Administration (FDA) has approved a new class of danteles, one of the world’s most popular sweet treats, for children to eat on a limited basis.
The FDA on Thursday approved a novel formulation of the drug called dantelle, which has been used in dantella cake, dantels flambées and other desserts.
The product will be licensed to pharmacies by June 30, the FDA said in a statement.
Dantelé, a synthetic chemical, was developed by researchers at the University of California at Berkeley and the National Institutes of Health, with the goal of creating a more palatable version of dandelion flowers, which are eaten in Europe.
The drug is approved for use as a dietary supplement for those with chronic conditions such as cancer and arthritis.
The drug is an effective treatment for some conditions and has been shown to reduce the risk of certain types of cancer.
It was initially marketed as a way to treat migraines and migraine-related seizures.
Dont miss a thing – sign up for our newsletter!
Sign up here to receive our free newsletters.
“We think dantelles are really the perfect food for children,” said Dr. William J. Smith, director of the UCLA School of Medicine’s Department of Biological and Molecular Pharmacology.
“They’re so delicious, and we think that’s what people are looking for.”
The FDA said it has not yet approved dantles as a food additive.
The agency will begin evaluating dantele as a treatment for other types of disorders and cancer.
The Food and Drugs Administration approved dantelette in 2010 and dantelface in 2013.
The agency did not say when the drug might be available in the United States.
It said dantelin was approved in 2005 for use in treating irritable bowel syndrome and Crohn’s disease.
The U.K.-based company is developing dantelnades for use by children and adults in developing countries.